NCT02309593终止不适用
Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- Component Survivorship
研究概览
简要总结
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU). These types of studies are required by regulatory authorities for all THA and resurfacing devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with the medial device directives (MEDDEV) 2.12/2 rev 2.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject previously underwent / is a candidate for primary THA for any of the following:
- •Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia
- •Inflammatory degenerative joint disease such as rheumatoid arthritis; or
- •Correction of functional deformity
- •Subject has been previously implanted / is a candidate to be implanted with the specified combination of components
- •Subject is willing and able to complete required study visits or assessments
- •Not previously implanted subject is able to undergo primary THA procedure
- •Previously implanted bilateral subjects can have both THAs enrolled in the study provided:
- •the specified combination of components were implanted in both
- •all other aspects of the Inclusion/Exclusion Criteria are satisfied
- •enrollment does not exceed the subject count specified in the Clinical Trial Agreement
- •the subject agrees to a second Informed Consent document specific to the second THA
- •Prospective enrollment of a previously unimplanted contralateral hip is permitted in this study provided:
- •it occurs not more than two years after the index THA
- •the specified combination of components is used
- •all other aspects of the Inclusion/Exclusion Criteria are satisfied
- •enrollment does not exceed the subject count specified in the Clinical Trial Agreement
- •the subject agrees to a second Informed Consent document specific to the second THA
排除标准
- •Subject is skeletally immature (less than 21 years of age) at time of primary THA surgery
- •Subject is currently enrolled in another clinical study which could affect the endpoints of this protocol
- •Subject is unwilling to sign the Informed Consent document
- •Subject has substance abuse issues
- •Subject is incarcerated or has pending incarceration
- •Subject is anticipated to require a contralateral THA less than 1 year after the index THA on the enrolled hip
- •In addition, not previously implanted subjects will be excluded if they meet any of the following criteria:
- •Subject has any of the following contraindications at the time of implantation
- •Overt infection
- •Distant foci of infections (which may cause hematogenous spread to the implant site)
- •Rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram
- •Inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable
- •Neuropathic joints
- •Hepatitis or HIV infection
- •Neurological or musculoskeletal disease that may adversely affect gait or weight-bearing
结局指标
主要结局
Component Survivorship
时间窗: 10 years post-operative
The primary objective of this study is to estimate survivorship of all components at specified intervals out to 10 years follow-up.
次要结局
- Patient functional outcomes (quality of life)(Previously implanted subjects: 6 months, 1, 3, 5, 7, and 10 years postoperatively beginning with first available visit; not previously implanted subjects: Pre-operative, 6 months, 1, 3, 5, 7, and 10 years postoperatively.)
- Patient functional outcomes (hip specific)(Previously implanted subjects: 6 months, 1, 3, 5, 7, and 10 years postoperatively beginning with first available visit; not previously implanted subjects: Pre-operative, 6 months, 1, 3, 5, 7, and 10 years postoperatively.)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular ComponentsJoint DiseaseNCT02823834MicroPort Orthopedics Inc.121
终止
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral StemsJoint DiseaseNCT02397746MicroPort Orthopedics Inc.75
进行中（未招募）
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Preserve Femoral StemJoint DiseaseNCT03865667MicroPort Orthopedics Inc.63
Enrolling By Invitation
不适用
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular ComponentsJoint DiseaseNCT03576573MicroPort Orthopedics Inc.143
终止
不适用
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral StemsJoint DiseaseNCT02314611MicroPort Orthopedics Inc.154